News

2025.10.09News Release

Maruho Announces Exclusive Out-Licensing Agreement with Hyphens for In Vitro Diagnostic (Varicella-Zoster Virus Antigen Kit) in 10 ASEAN Countries

2025.10.01Notification

Maruho Co., Ltd. has deconsolidated Maruho Hatsujyo Kogyo Co., Ltd.​

2025.09.30News Release

Maruho Announces Strategic minority Investment in Sibel Health

2024.07.01News Release

Maruho and Sibel Health Enter into a Worldwide Collaborative Development and Commercialization Agreement for a New Digital Health Technology for Itch

2024.06.11News Release

Maruho Launches "Mitchga Subcutaneous Injection 30mg Vials", an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis in Japan

2024.06.05News Release

Maruho and Hyphens Pharma Announce Exclusive License Agreement for Anti-herpes Virus Agent (INN: Amenamevir) in 10 ASEAN Countries

2024.04.01Notification

Posted Activity Report "Maruho Report 2023" (English version)

2024.03.26News Release

Maruho Acquires Manufacturing and Marketing Approval in Japan for "Mitchga Subcutaneous Injection 30mg Vials", an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis

2024.02.22News Release

Maruho Establishes Local Subsidiary in China

2024.01.10News Release

AOBiome and Maruho have entered into an Exclusive License Agreement for a Novel Therapeutic for the treatment of Atopic Dermatitis in Japan

2023.10.01Notification

Organization changes

2023.09.07News Release

Maruho and Journey Medical Corporation Enter into an Exclusive License Agreement for a Hyperhidrosis Treatment (Topical Anticholinergic Agent) in Asia

2023.07.03News Release

Maruho and Alchemedicine Enter into Exclusive License Agreement for Aldehyde Dehydrogenase 2 (ALDH2) Activator

2023.04.27News Release

Maruho Enters a License Agreement with Nielsen BioSciences for the Treatment of Verruca Vulgaris (Common Warts) in Japan

2023.03.01Notification

Renewed the Corporate Philosophy and Vision Page.

2023.02.24News Release

Maruho Receives Manufacturing and Marketing Approval for a Partial Change of the Indication and Dosage/Administration for Anti-herpes Virus Agent "Amenalief Tab. 200mg" for the Treatment of Recurrent Herpes Simplex in Japan